{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T10:02:35Z","timestamp":1769508155432,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T00:00:00Z","timestamp":1735862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"DOI":"10.1007\/s00296-024-05771-6","type":"journal-article","created":{"date-parts":[[2025,1,3]],"date-time":"2025-01-03T05:18:23Z","timestamp":1735881503000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Similar Hepatitis B virus reactivation risk for patients with inflammatory arthritis or connective tissue diseases: a multicenter retrospective study"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1296-0693","authenticated-orcid":false,"given":"Maria","family":"Pappa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4215-3078","authenticated-orcid":false,"given":"Alexandra","family":"Koutsogianni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3006-9362","authenticated-orcid":false,"given":"Anastasios","family":"Karamanakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-7624-9738","authenticated-orcid":false,"given":"Niki","family":"Kyriazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrto","family":"Cheila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-2305-5328","authenticated-orcid":false,"given":"Dimitra","family":"Moschou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2036-9596","authenticated-orcid":false,"given":"Evangelia","family":"Mole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Souzana","family":"Gazi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evangelos","family":"Papadimitriou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9328-3075","authenticated-orcid":false,"given":"Fabiola","family":"Atzeni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1294-6421","authenticated-orcid":false,"given":"Marco","family":"Sebastiani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3399-9212","authenticated-orcid":false,"given":"Ourania D.","family":"Argyropoulou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1783-1939","authenticated-orcid":false,"given":"Konstantinos D.","family":"Vasilakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6207-496X","authenticated-orcid":false,"given":"Charalampos","family":"Papagoras","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4932-7023","authenticated-orcid":false,"given":"George E.","family":"Fragoulis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-6230","authenticated-orcid":false,"given":"Theodoros","family":"Androutsakos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,1,3]]},"reference":[{"key":"5771_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1759720X19868901","volume":"11","author":"GE Fragoulis","year":"2019","unstructured":"Fragoulis GE, Sipsas NV (2019) When rheumatology and infectious disease come together. Ther Adv Musculoskelet Dis 11:1\u20133. https:\/\/doi.org\/10.1177\/1759720X19868901","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"5771_CR2","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","volume":"79","author":"JD Isaacs","year":"2020","unstructured":"Isaacs JD, Burmester GR (2020) Smart battles: Immunosuppression versus Immunomodulation in the inflammatory RMDs. Ann Rheum Dis 79:991\u2013993. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218019","journal-title":"Ann Rheum Dis"},{"key":"5771_CR3","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1097\/BOR.0000000000000490","volume":"30","author":"O Shamriz","year":"2018","unstructured":"Shamriz O, Shoenfeld Y, Infections (2018) A double-edge sword in autoimmunity. Curr Opin Rheumatol 30:365\u2013372. https:\/\/doi.org\/10.1097\/BOR.0000000000000490","journal-title":"Curr Opin Rheumatol"},{"key":"5771_CR4","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1007\/s00296-019-04437-y","volume":"39","author":"B Toka","year":"2019","unstructured":"Toka B, Eminler AT, G\u00f6n\u00fcll\u00fc E, Tozlu M, Uslan MI, Parlak E et al (2019) Rheumatologists\u2019 awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatol Int 39:2077\u20132085. https:\/\/doi.org\/10.1007\/s00296-019-04437-y","journal-title":"Rheumatol Int"},{"key":"5771_CR5","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1136\/ard-2022-223335","volume":"82","author":"GE Fragoulis","year":"2023","unstructured":"Fragoulis GE, Nikiphorou E, Dey M, Zhao SS, Courvoisier DS, Arnaud L et al (2023) 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis 82:742\u2013753. https:\/\/doi.org\/10.1136\/ard-2022-223335","journal-title":"Ann Rheum Dis"},{"key":"5771_CR6","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1111\/1756-185X.13010","volume":"20","author":"L-F Chen","year":"2017","unstructured":"Chen L-F, Mo Y-Q, Jing J, Ma J-D, Zheng D-H, Dai L (2017) Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. Int J Rheum Dis 20:859\u2013869. https:\/\/doi.org\/10.1111\/1756-185X.13010","journal-title":"Int J Rheum Dis"},{"key":"5771_CR7","doi-asserted-by":"publisher","first-page":"SI252","DOI":"10.1093\/rheumatology\/kead243","volume":"62","author":"S Katelani","year":"2023","unstructured":"Katelani S, Fragoulis GE, Bakasis AD, Pouliakis A, Nikiphorou E, Atzeni F et al (2023) HBV reactivation in patients with rheumatoid arthritis treated with anti-interleukin-6: a systematic review and meta-analysis. Rheumatol (United Kingdom) 62:SI252\u2013SI259. https:\/\/doi.org\/10.1093\/rheumatology\/kead243","journal-title":"Rheumatol (United Kingdom)"},{"key":"5771_CR8","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1136\/ard.2009.127233","volume":"69","author":"D Vassilopoulos","year":"2010","unstructured":"Vassilopoulos D, Apostolopoulou A, Hadziyannis E, Papatheodoridis GV, Manolakopoulos S, Koskinas J et al (2010) Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. Ann Rheum Dis 69:1352\u20131355. https:\/\/doi.org\/10.1136\/ard.2009.127233","journal-title":"Ann Rheum Dis"},{"key":"5771_CR9","doi-asserted-by":"publisher","unstructured":"Chang Y, Jeong SW, Jang JY, Hepatitis B (2022) Virus Reactivation Associated with therapeutic interventions. Front Med (Lausanne) 8. https:\/\/doi.org\/10.3389\/fmed.2021.770124","DOI":"10.3389\/fmed.2021.770124"},{"key":"5771_CR10","doi-asserted-by":"publisher","unstructured":"Anvari S, Tsoi K (2024) Hepatitis B Virus Reactivation with Immunosuppression: a hidden threat? J Clin Med 13. https:\/\/doi.org\/10.3390\/jcm13020393","DOI":"10.3390\/jcm13020393"},{"key":"5771_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.31138\/MJR.31.1.129","volume":"31","author":"K Thomas","year":"2020","unstructured":"Thomas K, Vassilopoulos D (2020) Infections in patients with rheumatoid arthritis in the era of targeted synthetic therapies. Mediterr J Rheumatol 31:129\u2013136. https:\/\/doi.org\/10.31138\/MJR.31.1.129","journal-title":"Mediterr J Rheumatol"},{"key":"5771_CR12","doi-asserted-by":"publisher","unstructured":"Lee YH, Bae S-C, Song GG, Lee YH, Bae S-C, Song GG (2013) Hepatitis B virus (HBV) reactivation in rheumatic patients with hepatitis core antigen (HBV occult carriers) undergoing anti-tumour necrosis factor therapy. https:\/\/doi.org\/10.1111\/1756-185X.12154","DOI":"10.1111\/1756-185X.12154"},{"key":"5771_CR13","doi-asserted-by":"publisher","unstructured":"Fragoulis GE, Dey M, Zhao S, Schoones J, Courvoisier D, Galloway J et al (2022) Systematic literature review informing the 2022 EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in adults with autoimmune inflammatory rheumatic diseases. RMD Open 8. https:\/\/doi.org\/10.1136\/rmdopen-2022-002726","DOI":"10.1136\/rmdopen-2022-002726"},{"key":"5771_CR14","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1053\/j.gastro.2017.02.009","volume":"152","author":"R Loomba","year":"2017","unstructured":"Loomba R, Liang TJ, Hepatitis B (2017) Reactivation Associated with Immune suppressive and biological modifier therapies: current concepts, Management Strategies, and future directions. Gastroenterology 152:1297\u20131309. https:\/\/doi.org\/10.1053\/j.gastro.2017.02.009","journal-title":"Gastroenterology"},{"key":"5771_CR15","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1053\/j.gastro.2014.10.038","volume":"148","author":"RP Perrillo","year":"2015","unstructured":"Perrillo RP, Gish R, Falck-Ytter YT (2015) American Gastroenterological Association Institute Technical Review on Prevention and Treatment of Hepatitis B Virus Reactivation during Immunosuppressive Drug Therapy. Gastroenterology 148:221\u2013244e3. https:\/\/doi.org\/10.1053\/j.gastro.2014.10.038","journal-title":"Gastroenterology"},{"key":"5771_CR16","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1016\/j.jhep.2022.07.003","volume":"77","author":"GV Papatheodoridis","year":"2022","unstructured":"Papatheodoridis GV, Lekakis V, Voulgaris T, Lampertico P, Berg T, Chan HLY et al (2022) Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: a systematic review, meta-analysis, and expert opinion. J Hepatol 77:1670\u20131689. https:\/\/doi.org\/10.1016\/j.jhep.2022.07.003","journal-title":"J Hepatol"},{"key":"5771_CR17","doi-asserted-by":"publisher","unstructured":"Myint A, Tong MJ, Beaven SW (2020) Reactivation of Hepatitis B virus: a review of clinical guidelines. 15. https:\/\/doi.org\/10.1002\/cld.883","DOI":"10.1002\/cld.883"},{"key":"5771_CR18","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1002\/acr.23346","volume":"70","author":"TC Lin","year":"2018","unstructured":"Lin TC, Yoshida K, Tedeschi SK, de Abreu MM, Hashemi N, Solomon DH (2018) Risk of Hepatitis B Virus Reactivation in patients with inflammatory arthritis receiving Disease-modifying antirheumatic drugs: a systematic review and Meta-analysis. Arthritis Care Res (Hoboken) 70:724\u2013731. https:\/\/doi.org\/10.1002\/acr.23346","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5771_CR19","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1111\/liv.12154","volume":"33","author":"FW Chen","year":"2013","unstructured":"Chen FW, Coyle L, Jones BE, Pattullo V (2013) Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 33:1203\u20131210. https:\/\/doi.org\/10.1111\/liv.12154","journal-title":"Liver Int"},{"key":"5771_CR20","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1001\/jama.2014.15704","volume":"312","author":"H Huang","year":"2014","unstructured":"Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W et al (2014) Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA - J Am Med Association 312:2521\u20132530. https:\/\/doi.org\/10.1001\/jama.2014.15704","journal-title":"JAMA - J Am Med Association"},{"key":"5771_CR21","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1097\/MD.0b013e3182380a76","volume":"90","author":"R P\u00e9rez-Alvarez","year":"2011","unstructured":"P\u00e9rez-Alvarez R, D\u00edaz-Lagares C, Garc\u00eda-Hern\u00e1ndez F, Lopez-Roses L, Brito-Zer\u00f3n P, P\u00e9rez-de-Lis M et al (2011) Hepatitis B Virus (HBV) reactivation in patients receiving tumor necrosis factor (TNF)-Targeted therapy. Medicine 90:359\u2013371. https:\/\/doi.org\/10.1097\/MD.0b013e3182380a76","journal-title":"Medicine"},{"key":"5771_CR22","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1007\/s00296-022-05169-2","volume":"43","author":"E Capkin","year":"2023","unstructured":"Capkin E, Yaz\u0131c\u0131 A, Karkucak M, Durmaz Y, Toprak M, Ataman \u015e et al (2023) Evaluation of hepatitis serology and frequency of viral reactivation in patients with inflammatory arthritis receiving biologic agents: a multicenter observational study. Rheumatol Int 43:523\u2013531. https:\/\/doi.org\/10.1007\/s00296-022-05169-2","journal-title":"Rheumatol Int"},{"key":"5771_CR23","doi-asserted-by":"publisher","first-page":"R179","DOI":"10.1186\/ar2868","volume":"11","author":"C Charpin","year":"2009","unstructured":"Charpin C, Guis S, Colson P, Borentain P, Matt\u00e9i J-P, Alcaraz P et al (2009) Safety of TNF-blocking agents in rheumatic patients with serology suggesting past Hepatitis B state: results from a cohort of 21 patients. Arthritis Res Ther 11:R179. https:\/\/doi.org\/10.1186\/ar2868","journal-title":"Arthritis Res Ther"},{"key":"5771_CR24","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1007\/s10620-020-06725-1","volume":"66","author":"MH Kuo","year":"2021","unstructured":"Kuo MH, Tseng CW, Lu MC, Tung CH, Tseng KC, Huang KY et al (2021) Risk of Hepatitis B Virus Reactivation in Rheumatoid Arthritis patients undergoing Tocilizumab-Containing treatment. Dig Dis Sci 66:4026\u20134034. https:\/\/doi.org\/10.1007\/s10620-020-06725-1","journal-title":"Dig Dis Sci"},{"key":"5771_CR25","doi-asserted-by":"publisher","unstructured":"Chen L-F, Mo Y-Q, Jing J, Ma J-D, Zheng D-H, Dai L (2017) Short-course tocilizumab increases risk of hepatitis B virus reactivation in patients with rheumatoid arthritis: a prospective clinical observation. https:\/\/doi.org\/10.1111\/1756-185X.13010","DOI":"10.1111\/1756-185X.13010"},{"key":"5771_CR26","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.jmii.2017.04.002","volume":"52","author":"C-T Lin","year":"2019","unstructured":"Lin C-T, Huang W-N, Hsieh C-W, Chen Y-M, Chen D-Y, Hsieh T-Y et al (2019) Safety and effectiveness of tocilizumab in treating patients with rheumatoid arthritis \u2013 a three-year study in Taiwan. J Microbiol Immunol Infect 52:141\u2013150. https:\/\/doi.org\/10.1016\/j.jmii.2017.04.002","journal-title":"J Microbiol Immunol Infect"},{"key":"5771_CR27","doi-asserted-by":"publisher","first-page":"2369","DOI":"10.1007\/s10067-023-06630-8","volume":"42","author":"S Liu","year":"2023","unstructured":"Liu S, He Z, Wu W, Jin H, Cui Y (2023) Safety of secukinumab in the treatment of patients with axial spondyloarthritis and concurrent hepatitis B virus infection or latent tuberculosis infection. Clin Rheumatol 42:2369\u20132376. https:\/\/doi.org\/10.1007\/s10067-023-06630-8","journal-title":"Clin Rheumatol"},{"key":"5771_CR28","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1136\/annrheumdis-2021-220774","volume":"80","author":"M-H Chen","year":"2021","unstructured":"Chen M-H, Lee I-C, Chen M-H, Hou M-C, Tsai C-Y, Huang Y-H (2021) Abatacept is second to rituximab at risk of HBsAg reverse seroconversion in patients with rheumatic disease. Ann Rheum Dis 80:1393\u20131399. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220774","journal-title":"Ann Rheum Dis"},{"key":"5771_CR29","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1136\/annrheumdis-2017-211322","volume":"77","author":"YM Chen","year":"2018","unstructured":"Chen YM, Huang WN, Wu Y, Da, Lin CT, Chen YH, Chen DY et al (2018) Reactivation of hepatitis B virus infection in patients with rheumatoid arthritis receiving tofacitinib: a real-world study. Ann Rheum Dis 77:780\u2013782. https:\/\/doi.org\/10.1136\/annrheumdis-2017-211322","journal-title":"Ann Rheum Dis"},{"key":"5771_CR30","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1111\/liv.15793","volume":"44","author":"MH Kuo","year":"2024","unstructured":"Kuo MH, Tseng C, Ko P, Wang S, Lu M, Tung C et al (2024) HBV reactivation in HBsAg\u2013\/HBcAb\u2009+\u2009rheumatoid arthritis patients receiving biologic\/targeted synthetic DMARDs. Liver Int 44:497\u2013507. https:\/\/doi.org\/10.1111\/liv.15793","journal-title":"Liver Int"},{"key":"5771_CR31","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1111\/1756-185X.13582","volume":"22","author":"Y Chen","year":"2019","unstructured":"Chen Y, Chen H, Huang W, Chen Y, Hsieh T, Yang S et al (2019) Reactivation of hepatitis B virus infection following rituximab treatment in HBsAg-negative, HBcAb\u2010positive rheumatoid arthritis patients: a long\u2010term, real\u2010world observation. Int J Rheum Dis 22:1145\u20131151. https:\/\/doi.org\/10.1111\/1756-185X.13582","journal-title":"Int J Rheum Dis"},{"key":"5771_CR32","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1177\/0961203317711009","volume":"27","author":"WT Lin","year":"2018","unstructured":"Lin WT, Chen YM, Chen DY, Lan JL, Chang CS, Yeh HZ et al (2018) Increased risk of hepatitis B virus reactivation in systemic lupus erythematosus patients receiving immunosuppressants: a retrospective cohort study. Lupus 27:66\u201375. https:\/\/doi.org\/10.1177\/0961203317711009","journal-title":"Lupus"},{"key":"5771_CR33","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/j.1365-2133.2007.08058.x","volume":"157","author":"CH Yang","year":"2007","unstructured":"Yang CH, Wu TS, Chiu CT (2007) Chronic hepatitis B reactivation: a word of caution regarding the use of systemic glucocorticosteroid therapy. Br J Dermatol 157:587\u2013590. https:\/\/doi.org\/10.1111\/j.1365-2133.2007.08058.x","journal-title":"Br J Dermatol"},{"key":"5771_CR34","doi-asserted-by":"publisher","unstructured":"Chen M-H, Chen M-H, Liu C-Y, Tsai C-Y, Huang D-F, Lin H-Y et al (2016) Hepatitis B Virus Reactivation in Rheumatoid Arthritis patients undergoing Biologics Treatment. https:\/\/doi.org\/10.1093\/infdis\/jiw606","DOI":"10.1093\/infdis\/jiw606"},{"key":"5771_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jmii.2017.10.002","volume":"52","author":"YM Chen","year":"2019","unstructured":"Chen YM, Yang SS, Chen DY (2019) Risk-stratified management strategies for HBV reactivation in RA patients receiving biological and targeted therapy: a narrative review. J Microbiol Immunol Infect 52:1\u20138. https:\/\/doi.org\/10.1016\/j.jmii.2017.10.002","journal-title":"J Microbiol Immunol Infect"},{"key":"5771_CR36","doi-asserted-by":"publisher","unstructured":"Tien YC, Yen HH, Li CF, Liu MP, Hsue YT, Hung MH et al (2018) Changes in hepatitis B virus surface antibody titer and risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients undergoing biologic therapy for rheumatic diseases: a prospective cohort study. Arthritis Res Ther 20. https:\/\/doi.org\/10.1186\/s13075-018-1748-z","DOI":"10.1186\/s13075-018-1748-z"},{"key":"5771_CR37","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ajco.13050","volume":"15","author":"T Kotake","year":"2019","unstructured":"Kotake T, Satake H, Okita Y, Hatachi Y, Hamada M, Omiya M et al (2019) Prevalence and risk factors of hepatitis B virus reactivation in patients with solid tumors with resolved HBV infection. Asia Pac J Clin Oncol 15:63\u201368. https:\/\/doi.org\/10.1111\/ajco.13050","journal-title":"Asia Pac J Clin Oncol"},{"key":"5771_CR38","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1136\/annrheumdis-2016-209973","volume":"76","author":"W Fukuda","year":"2017","unstructured":"Fukuda W, Hanyu T, Katayama M, Mizuki S, Okada A, Miyata M et al (2017) Incidence of hepatitis B virus reactivation in patients with resolved infection on immunosuppressive therapy for rheumatic disease: a multicentre, prospective, observational study in Japan. Ann Rheum Dis 76:1051\u20131056. https:\/\/doi.org\/10.1136\/annrheumdis-2016-209973","journal-title":"Ann Rheum Dis"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-024-05771-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-024-05771-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T06:38:33Z","timestamp":1737700713000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-024-05771-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,3]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["5771"],"URL":"https:\/\/doi.org\/10.1007\/s00296-024-05771-6","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,3]]},"assertion":[{"value":"6 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was obtained from the Institutional Board of \u201cLaiko\u201d Hospital Scientific Council (Protocol No. 19\/968, July 2019), and all participants provided written informed consent according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"The authors declare no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"15"}}